Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed Breast cancer~* Metastatic Breast Cancer currently of stage IV disease or unresectable locoregionally recurrent breast cancer~* refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy~* At least 14 days from the completion of any previous cancer therapy~* Adequate organ function~* Life expectancy of 3 months or more~* Willing and able to comply with the protocol and able to understand and willing to sign an informed consent~Key Exclusion Criteria:~* Previously treated with eribulin~* Peripheral neuropathy Grade ≥3~* Receipt of prior CXCR4 therapy~* Receipt of colony stimulating factors (CSFs) filgrastim, pegfilgrastim, or sargramostim, or radiation therapy within 14 days prior to study Day 1~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to balixafortide or eribulin or other agents used in the study~* Breast feeding or pregnant~* Patients with congestive heart failure, electrolyte abnormalities, bradyarrhythmias, known congenital long QT syndrome, QT interval corrected with Fridericia's formula (QTcF) ≥470 msec at baseline in the absence of bundle branch block, or currently taking drugs at known risk of prolonging the QT interval or causing torsades de pointes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eribulin (Type: ACTIVE_COMPARATOR): None
- Balixafortide + Eribulin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).